Two Giants Dominate IHE, Making It Riskier Than It Looks
As of March 2026, the iShares U.S. Pharmaceuticals ETF is heavily keyed to two drugmakers, exposing investors to outs...
Learn when to rebalance dividend ETFs in retirement with simple, actionable guidance. This concise intro explains timing cues and practical steps for steady retirement income.
12,627 articlesAs of March 2026, the iShares U.S. Pharmaceuticals ETF is heavily keyed to two drugmakers, exposing investors to outs...
The AI rally around optics stocks like Lumentum has turned heads. But a single red flag can derail gains. This guide ...
Mega IPOs spark big bets and bigger headlines. This guide unpacks whether elon musk selling 'hopium' is fueling Space...
A well-known tech software ETF faced heavy selling, but its comeback shows the staying power of enterprise software a...
The Tortoise AI Infrastructure ETF (TCAI) is drawing attention as data-center power, cooling, and fiber networks surg...
SpaceX’s public debut could bring huge hype and big risks for everyday investors. This guide breaks down the mechanic...
MAGY, the MAGY Magnificent Seven Covered Call ETF, now offers a Monday-morning income payout. The fund uses an active...
As rates rise, some brokers benefit from higher interest income. This piece explains how Interactive Brokers can gene...
As July 2026 unfolds, the two JPMorgan income ETFs clash over safety versus yield. This piece weighs performance, pay...
Oil climbs back above $100 as two popular ETFs diverge in their bets. This report weighs the outlook for oih: driller...
A trio of income funds approaches yields in very different ways, highlighting a key question for retirees: how much u...
The S&P 500 has slipped from its January peak, creating a dilemma for investors: chase a rebound or wait for more cla...